RECLAIM STUDY: A Phase 2 Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol Use Disorder (AUD) in Subjects With Obesity or Overweight

NCT06987513 · Active, not recruiting

Last updated 2026-05-28

This clinical trial is testing whether the medication pemvidutide can help reduce heavy drinking days in adults with alcohol use disorder who are also overweight or obese.

Status Active, not recruiting Ongoing, but no longer enrolling new participants.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, quadruple-blind treatment study

Participants 100 people

Who can join Ages 18–75 · all sexes

Timeline Started 2025-05 · est. completion 2026-06

Where 12 sites · United States

What this study is testing ClinicalTrials.gov NCT06987513 ↗

Description as written by the study sponsor.

This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of pemvidutide in the treatment of AUD in subjects with obesity or overweight. After signing the informed consent form, subjects will be screened and if eligible randomized 1:1 to 1 of the following 2 treatment arms: * Pemvidutide: 2.4 mg SC once weekly * Placebo: Placebo SC once weekly

Treatments tested

Pemvidutide Drug

Pemvidutide 2.4mg
Placebo Other

Subcutaneous injection

Main thing measured	Change from baseline in the average number of heavy drinking days per week, with a heavy drinking day defined as 5 or more drinks in the day for men and 4 or more drinks in the day for women, using the TLFB method
Sponsor	Altimmune, Inc.
Conditions studied	Alcohol Use Disorder (AUD)
GLP-1 drugs	pemvidutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06987513 ↗